Amgen’s Repatha Cholesterol-Lowering Shot Poised for Sales Boost After Landmark CV Prevention Trial Success
Amgen announced that its cholesterol-lowering injection, Repatha (evolocumab), successfully prevented major cardiovascular events—including heart disease death, heart attack, and ischemic stroke—in a large Phase 3 trial (VESALIUS-CV) of 12,000 high-risk patients with no prior heart attack or stroke13.
The VESALIUS-CV trial met both dual primary endpoints, demonstrating statistically and clinically significant reductions in cardiovascular events when Repatha was added to standard LDL-lowering therapy, compared to standard therapy alone3.
Repatha now becomes the first and only PCSK9 inhibitor to show significant cardiovascular event reduction for both primary and secondary prevention populations, potentially expanding its eligible patient pool to tens of millions globally3.
Analysts state these data could considerably increase Repatha's market reach, as current penetration remains in the low single digits despite a large addressable population of patients not meeting LDL cholesterol goals1.
Repatha global sales reached $2.2 billion in 2024, up 36% from the previous year, with expectations that trial success could further accelerate uptake1.
Economic analyses show Repatha is cost-effective for high-risk cardiovascular patients when priced competitively, especially for those with established atherosclerotic cardiovascular disease (ASCVD)2.
No new safety signals were identified in the VESALIUS-CV trial, supporting Repatha's established safety profile for broader use3.
Amgen will present full results at the American Heart Association Scientific Sessions on November 8, 2025, and submit the findings for peer-reviewed publication3.
Sources:
1. https://www.statnews.com/2025/10/02/amgen-repatha-heart-attacks-disease/
2. https://sciencebusiness.net/news/life-sciences/amgen-new-economic-analysis-cholesterol-lowering-drug-repatha
3. https://www.prnewswire.com/news-releases/landmark-phase-3-trial-vesalius-cv-meets-primary-endpoints-in-a-cardiovascular-primary-prevention-study-of-12-000-patients-302573412.html